TrivarX Advances AI-Powered Depression Screening with Veterans Affairs Clinical Trial
Key Insights
TrivarX (search) received Institutional Review Board approval to begin a 60-patient clinical trial screening for current major depressive episodes using AI technology in partnership with the US Department of Veterans Affairs.
The trial will test whether TRI's AI algorithm can effectively detect mental health conditions (search) through sleep data using single-channel ECG technology compatible with wearable devices like smartwatches.
Previous Phase 2 studies demonstrated promising results with 87% sensitivity and 67% specificity in identifying current major depressive episodes, potentially addressing the growing mental health crisis that has seen claims surge from $1.2 billion to $2.2 billion between 2019-2024.
TrivarX (search) (ASX: TRI) has received Institutional Review Board (IRB) approval to commence a clinical trial evaluating AI-powered screening for current major depressive episodes (cMDE), marking a significant step toward bringing objective mental health detection to the wearables market.
The 60-patient trial will be conducted in partnership with the Greater Los Angeles Veterans Research and Education Foundation (search) (GLAVREF) and the United States Department of Veterans Affairs, with first enrollments expected in the coming weeks. A Cooperative Research and Development Agreement (CRADA) has been executed with GLAVREF and the VA to formalize the collaboration.
Trial Design and Objectives
The study aims to evaluate whether TRI's AI algorithm can effectively screen for current major depressive episodes using sleep data collected through single-channel ECG technology. This represents a crucial advancement as single-channel ECG is the technology used in consumer devices like smartwatches, potentially enabling widespread deployment of the screening tool.
Patients will be recruited across multiple VA sites, with study completion expected within 12 weeks from commencement. The trial specifically targets veterans with suspected sleep apnea (search), allowing researchers to assess the algorithm's effectiveness in detecting both mental health conditions (search) and sleep disorders (search) simultaneously.
Building on Promising Early Results
The current trial builds upon encouraging Phase 2 study results that demonstrated 87% sensitivity and 67% specificity in identifying current major depressive episodes. These metrics suggest the AI algorithm shows substantial promise for accurate mental health screening through objective biological markers rather than traditional patient questionnaires.
The partnership with the Veterans Health Administration, which serves 9.1 million veterans annually as the largest integrated healthcare system in the United States, could provide significant validation and commercialization opportunities if the trial proves successful.
Addressing Growing Mental Health Crisis
The timing of this trial coincides with mounting concerns about the mental health crisis and its economic impact. Recent data shows mental health claims in Australia have nearly doubled from $1.2 billion in 2019 to $2.2 billion in 2024, creating sustainability challenges for insurance companies.
Labor MP Mike Freelander has highlighted overdiagnosis of mental health problems as contributing to an unsustainable surge in life insurance and workers' compensation claims. TRI's approach of using biological evidence through sleep data analysis could potentially address diagnostic accuracy concerns while providing objective screening capabilities.
Commercial Implications
Success in this VA trial could unlock substantial commercialization opportunities through partnerships with wearable device manufacturers. The ability to integrate mental health screening into consumer devices represents a significant market opportunity, particularly given the widespread adoption of fitness trackers and smartwatches.
The company's focus on objective detection and screening of mental health conditions (search) through AI-powered analysis of sleep patterns positions it at the intersection of two rapidly growing markets: wearable technology and digital mental health solutions.
Results from the 60-patient trial are expected approximately 12 weeks after the final patient enrollment, with the company having already recruited the first 10 patients in a parallel 30-patient trial focusing on veterans with suspected sleep apnea (search).